XEN1101 was found to be well-tolerated, with comparable adverse event rates across all treatment groups.
The trial is designed to analyse the safety and efficacy of 30mg and 60mg doses of ACP-204 versus those of placebo.
OmnImmune is an allogeneic unmodified cell therapy that consists of activated and expanded gamma delta T-cells.
Based on brepocitinib’s favourable safety and tolerability profile in the trial, Priovant will advance it for other indications.
Interim efficacy assessment data showed that the trial met the primary endpoint of progression-free survival.
Give your business an edge with our leading industry insights.
The trial is supported by a £2m grant from the UK National Institute for Health and Care Research.
The Queensland and Australian governments, as well as various partners, supported the trial of the re-engineered molecular clamp.
The company anticipates reporting topline findings from the trial in the first quarter of next year.
The trial will analyse whether early treatment with Silmitasertib hinders CAP progression.
The open-label trial is designed to assess the efficacy and safety of NXC-201.